Thursday, October 30, 2014 7:32:47 AM
In the United States, sales of Copaxone® amounted to $800 million, in line with sales in the third quarter of 2013. At the end of the third quarter of 2014, according to September 2014 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 28.3% and 32.2%, respectively. Copaxone® 40 mg/mL accounted for 55% of total Copaxone® prescriptions
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM